Skip to main content
Equibles
BIOA logo

BIOA · BioAge Labs, Inc. · Metrics

Track BIOA — free

Use BIOA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BIOA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.10 -0.43 (-7.78%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$234.07M
Shares
45.90M
Volume · Oct 23 465.87K Avg daily vol (3M) 948.42K

BIOA metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$5.10
Market cap
$234.07M

Price action

20 metrics
Price change (1W)
+5.4%
Price change (30D)
-27.7%
Price change (3M)
-76.6%
Price change (6M)
-70.1%
Price change (YTD)
-61.5%
Price change (1Y)
-35.8%
Trailing year
Price change (5Y)
—
52-week high
$25.10
52-week low
$4.84
Change from 52-week high
-79.7%
Change from 52-week low
+5.4%
Annualized volatility
104.7%
Annualized volatility (3M)
146.5%
Beta
1.8
RSI (14D)
28.0
Price vs SMA 50
-35.2%
Price vs SMA 200
-68.4%
Avg volume (3M)
948,424
Relative volume
0.5
Average dollar volume
$8.86M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
45.90M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-4.3×
EV / EBITDA
—
EV / EBIT
—
P / sales
22.6×
reciprocal yield 4.4%
P / book
0.6
reciprocal yield 160.2%
FCF yield
-37.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-40.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-09-30

Profitability

9 metrics
Gross margin
—
Operating margin
-1,026.3%
Trailing 12 months
Net margin
-912.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$106.27M
Net income (TTM)
−$94.46M
Trailing 12 months
Diluted EPS (TTM)
$-2.38
FCF margin
-850.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.26
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.68
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.39
Operating cash flow per diluted share (TTM)
$-2.22
Free cash flow per diluted share (TTM)
$-2.24
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$2.22
Stock compensation per diluted share (TTM)
$0.35
Book value per share
$7.28

Growth

11 metrics
Revenue growth YoY
+1.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$10.36M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+25.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-25.2%
Return on assets
-23.8%
Debt / equity
0.0
Current ratio
17.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$88.09M
Quick ratio
17.2
Interest coverage
-378.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$278.45M
Latest balance sheet
Cash & equivalents
$73.96M
Total assets
$396.93M
Total debt
$2.65M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$87.60M
Capital expenditures (TTM)
$488,000
R&D (TTM)
$87.79M
SG&A (TTM)
—
Stock compensation (TTM)
$14.04M
R&D / revenue
847.8%
Stock compensation / revenue
135.6%

Ownership (13F)

9 metrics
13F filers
150
13F filer change QoQ
+4
Institutional ownership
84.4%
Conviction holders (share of 13F filers)
4.7%
Crowding (high-turnover and private-fund holders)
44.6%
Private-fund adviser ownership
42.6%
Active holders' share change QoQ
+5.7%
Holder tenure
4.8
Price vs estimated holder cost
+56.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.2%

Short interest

3 metrics
Short interest
7.1%
Latest settlement · 3.9 days to cover
Days to cover
3.9d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1709941 CUSIP 09077V100 13F (30d) 11 filings 11 filers Visit website Investor relations